Unum Group's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Unum Group (UNM) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Unum Group vs Its Competitors
- TTM: Trailing 12-month revenue of 13,348M vs 2,134,982M combined for tracked competitors (0.6% combined share).
- Trending: Latest-quarter revenue run-rate is holding steady (+1.0% annualized vs trailing 12 months), vs holding steady (+1.3%) for its tracked peer group.
- Growth: Unum Group generated 0.3% revenue growth year over year in Q2 2026, vs 5.0% for its tracked competitors combined.
- Profitability: Its 7.6% net margin compares with 10.4% for the peer group.
- Scale: Unum Group ranks #8 of 14 companies by market capitalization in the Accident & Health Insurance industry, holding 2.1% of industry market cap.
- Peer revenue share: Unum Group accounted for 0.6% of combined revenue among its tracked peer group, down from 0.7% a year earlier.
- Peer differentiation: Revenue per employee of $1.22M compares with $1.34M for the peer group (0.9x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
UNM Sales vs. its Competitors, Q2 2026
Unum Group reported revenue growth of 0.26 % year on year in Q2 2026, below its competitors' combined revenue growth of 4.99 %.
With a net margin of 7.62 %, Unum Group reported lower profitability than its competitors (10.36 %).
Unum Group generated 0.62 % of the combined sales of its peer group, down from 0.65 % a year earlier.
Unum Group vs. its Competitors, Q2 2026
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Unum Group and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Unum Group | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar-Size Competitors (8) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (7) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Unum Group's competitor groups requires a Commercial License.
For context: the Accident & Health Insurance industry grew revenue 7.3% year over year, combined, vs 0.3% for Unum Group. Unum Group's share of combined industry revenue moved from 0.95% to 0.89%, a loss of 0.06 percentage points.
Unum Group's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Unum Group | Yes | Yes | No | No |
| Competitors combined (61) | ||||
| High-Confidence Competitors (1) | ||||
| Similar-Size Competitors (10) | ||||
| Similar Growth & Profitability (8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 12.50 % (1 of 8) | 0.00 % (0 of 8) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
UNM Stock Performance relative to its Competitors
UNM Stock Performance relative to High-Confidence Competitors
UNM Stock Performance relative to Similar-Size Competitors
UNM Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Centene Corporation | 282.9% | Outperformed |
| 2 | United Fire Group Inc | 282.9% | Outperformed |
| 3 | Humana Inc | 282.9% | Outperformed |
| 4 | Siriuspoint Ltd | 282.9% | Outperformed |
| 5 | Principal Financial Group inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Unum Group's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Unum Group's Comment on Competition and Industry Peers
In the United Kingdom, we compete for the individual and group products we sell with a number of large internationally recognized providers and strong local carriers. These providers have been aggressively trying to maintain market share in a difficult economic environment, characterized by very low interest rates and expense pressures on employers and individuals.
We believe the need for the types of products we offer is significant. In both the United States and the United Kingdom, individuals and families often live paycheck to paycheck with a considerable chance of being out of work. Pressure is also mounting on governments as to the sustainability of public assistance. Based on current penetration levels, we believe there is substantial upside growth potential.
All areas of the employee benefits markets are highly competitive due to the yearly renewable term nature of the group products and the large number of insurance companies offering products in this market. There is a risk that purchasers of employee benefits products may be able to obtain more favorable terms from competitors in lieu of renewing coverage with us. The effect of competition may, as a result, adversely affect the persistency of these and other products, as well as our ability to sell products in the future.
We must attract and retain independent agents and brokers to actively market our products. Strong competition exists among insurers for agents and brokers. We compete with other insurers for sales agents and brokers primarily on the basis of our product offerings, financial strength, support services, and compensation. Sales of our products could be materially adversely affected if we are unsuccessful in attracting and retaining agents and brokers.
Publicly Traded Peers of Unum Group
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Unum Group | 14,581.40 | 13,347.70 |
| Unitedhealth Group Incorporated | 342,313.98 | 450,129.00 |
| Futu Holdings Ltd | 126,960.16 | 2,935.37 |
| Elevance Health Inc | 85,981.16 | 201,113.00 |
| Marsh and Mclennan Companies Inc | 81,472.46 | 27,968.00 |
| The Cigna Group | 71,752.79 | 282,382.00 |
| SUBTOTAL | 1,598,843.07 | 2,346,287.14 |
Sign in to see all competitors of Unum Group.
Sources: Unum Group's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Unum Group versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Unum Group's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Aegon Ltd | Named by the company | 85% |
| Gritstone Bio Inc | Named by the company | 85% |
| Cno Financial Group Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Unum Group's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Unum Group's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Unum Group | Unum US 55.14 % |
| Unitedhealth Group Incorporated | UnitedHealthcare 76.78 % |
| Elevance Health Inc | Reportable 100.00 % |
| Marsh and Mclennan Companies Inc | Marsh Insurance Group 55.79 % |
| The Cigna Group | Evernorth 85.32 % |
| Metlife Inc | Group Benefits 36.13 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Unum Group's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Unum Group | 14,581 | 1,223,437 | 64,409 |
| Unitedhealth Group Incorporated | 342,314 | 1,154,177 | 38,236 |
| Futu Holdings Ltd | 126,960 | 14,531,554 | 7,188,465 |
| Elevance Health Inc | 85,981 | 2,071,195 | 51,040 |
| Marsh and Mclennan Companies Inc | 81,472 | 294,400 | 42,821 |
| The Cigna Group | 71,753 | 4,171,078 | 103,146 |
| PEERS TOTAL | 1,584,262 | 1,344,194 | 113,911 |
Unum Group's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Arthur J Gallagher and Co | Other Foreign 4.06 % |
| Aon Plc | Europe, Middle East, and Africa, Other Than United Kingdom and Ireland 16.91 % |
| Brown and Brown Inc | US 86.46 % |
| Citizens Inc | All Countries 66.88 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Unum Group's Position in Industry Market Structure
Market-capitalization share and concentration across all 14 companies in Unum Group's industry classification, broader than the peer set above. Market cap in millions of $.Unum Group ranks #8 of 14 companies by market capitalization in its industry, holding 2.07 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 2,760, indicating a highly concentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Unitedhealth Group Incorporated | 342,314 | 48.54 % |
| 2 | Elevance Health Inc | 85,981 | 12.19 % |
| 3 | The Cigna Group | 71,753 | 10.17 % |
| 4 | Aflac Incorporated | 57,408 | 8.14 % |
| 5 | Humana Inc | 1,234 | 5.2% |
| 6 | Centene Corporation | 1,234 | 5.2% |
| 7 | Principal Financial Group inc | 1,234 | 5.2% |
| 8 | Unum Group | 14,581 | 2.07 % |
| 9 | Oscar Health Inc | 1,234 | 5.2% |
| 10 | Molina Healthcare Inc | 1,234 | 5.2% |
Market cap and industry share for the rest of Unum Group's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-28.
Unum Group's Same-Size Peers & Stock Performance
Peers chosen by closeness in market-cap rank within the same industry classification (not the named-competitor list above). Trailing 12-month total return, 3-month price momentum, beta and Sharpe ratio vs the broad U.S. market.| Rank | Company | Market Cap | TTM Return |
|---|---|---|---|
| 3 | The Cigna Group | 71,753 | -4.19 % |
| 4 | Aflac Incorporated | 57,408 | 3.92 % |
| 5 | Humana Inc | 47,009 | 59.17 % |
| 6 | Centene Corporation | 31,097 | 81.97 % |
| 7 | Principal Financial Group inc | 1,234 | 12.3% |
| 8 | Unum Group | 14,581 | 19.77 % |
| 9 | Oscar Health Inc | 1,234 | 12.3% |
| 10 | Molina Healthcare Inc | 1,234 | 12.3% |
| 11 | Cno Financial Group Inc | 1,234 | 12.3% |
| 12 | Clover Health Investments Corp | 1,234 | 12.3% |
| 13 | Alignment Healthcare Inc | 1,234 | 12.3% |
Market cap, return, momentum, beta and Sharpe ratio for the rest of Unum Group's same-size peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation); returns and risk metrics as of 2026-09-28. Beta and Sharpe ratio are versus the broad U.S. equity market, not this industry.
Unum Group's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Accident & Health Insurance industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (16 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 53.43 % | 30.59 % (avg) | +22.8 pp |
| Operating Margin | 38.25 % | industry median | +34.4 pp |
| EBITDA Margin | 10.67 % | 6.78 % (avg) | +3.9 pp |
| Capital Intensity (Capex / Revenue) | 1.03 % | 0.39 % (avg) | +0.6 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Unum Group's Valuation vs Competitive Position
Valuation multiples vs the Accident & Health Insurance industry average (16 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 20.3x | 19.7x | +0.6x |
| EV / EBITDA | 12.2x | 15.8x | -3.6x |
| P/B | 1.3x | 2.4x | -1.1x |
| Return on Equity | 6.43 % | industry aggregate | -4.54 % |
| Return on Invested Capital | 12.30 % | 6.59 % (avg) | 5.72 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Unum Group's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 2.76 % | 3.45 % | 9.69 % | -8.72 % | -0.19 % | 3.29 % | 4.05 % | 1.46 % |
| Operating Margin | -10.41 % | 24.96 % | -63.39 % | 23.76 % | 28.14 % | 0.49 % | 5.96 % | 25.40 % |
| Return on Invested Capital | -4.58 % | 11.65 % | -29.53 % | 9.95 % | 6.96 % | 0.09 % | 1.05 % | 7.99 % |
| P/E | 14.1x | 5.6x | 5.8x | 6.3x | 6.3x | 6.8x | 7.8x | 18.2x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Unum Group's Strategic Group Map
Every company in Unum Group's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Unum Group is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Unum Group's BCG Growth-Share Matrix
Relative market share (vs Unum Group's largest competitor by market cap) against industry revenue growth, using the standard textbook thresholds (1.0x share, 10% growth) a common framework, not a precision instrument.
Unum Group falls in the Question Mark quadrant: relative market share of 0.04x vs its largest competitor, in an industry growing revenue 12.3% (median, trailing 12 months).
Source: CSIMarket API (market-cap share and industry revenue growth). The 10% growth and 1.0x share lines are standard textbook thresholds, not derived from this industry's own distribution. A caveat worth reading alongside this chart: Unitedhealth Group Incorporated alone holds 49% of this industry's market cap. In an industry this dominated by one leader, the framework will place nearly every OTHER company in "Dog" or "Question Mark" purely because relative share is measured against that leader, regardless of how strong those other companies actually are on their own fundamentals. Check the Profitability, Valuation and Financial Strength sections above before treating this quadrant label as a verdict.
Unum Group's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | Low | Industry HHI of 2,760 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | High (capital intensive) | Capital intensity (capex / revenue) of 1.03 % vs industry average 0.39 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Unum Group's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Unum Group's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Unum Group's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Unum Group falls in the Medium attractiveness / Low strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Unum Group's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 34.4 points above the industry median.
- Outperforming the U.S.A. 500 over the trailing 12 months.
Weaknesses
- Low relative market share vs the industry leader (0.04x).
Opportunities
- Industry revenue growing at a healthy 12.3% median pace.
Threats
- Industry dominated by Unitedhealth Group Incorporated, holding 48.54 % of industry market cap.
- High capital intensity requires continuous reinvestment just to keep pace with the industry.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Unum Group's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Unum Group | 0.00 | 0.46 | 0.48 |
| Unitedhealth Group Incorporated | 0.24 | 0.81 | 0.75 |
| Futu Holdings Ltd | 0.06 | 1.19 | 0.30 |
| Elevance Health Inc | 0.22 | 1.50 | 0.72 |
| Marsh and Mclennan Companies Inc | 0.68 | 1.13 | 1.33 |
| The Cigna Group | 0.12 | 0.82 | 0.76 |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Unum Group's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Unum Group | Q2 2026 | +0.3 % | -23.5 % |
| Unitedhealth Group Incorporated | Q2 2026 | +0.4 % | +58.7 % |
| Futu Holdings Ltd | Q4 2025 | +67.8 % | +107.6 % |
| Elevance Health Inc | Q2 2026 | +1.4 % | -16.1 % |
| Marsh and Mclennan Companies Inc | Q2 2026 | +6.1 % | +4.9 % |
| The Cigna Group | Q2 2026 | +6.7 % | +22.4 % |
| PEERS TOTAL | +6.1 % | +49.6 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Unum Group's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Unum Group | Q2 2026 | +3.1 % | +4.7 % |
| Unitedhealth Group Incorporated | Q2 2026 | +2.7 % | -9.8 % |
| Futu Holdings Ltd | Q4 2025 | +29.0 % | -67.4 % |
| Elevance Health Inc | Q2 2026 | +3.8 % | +7.5 % |
| Marsh and Mclennan Companies Inc | Q2 2026 | - | +22.0 % |
| The Cigna Group | Q2 2026 | +6.4 % | - |
Unum Group's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Unum Group | 1.11% | 4.27% | 9.05% |
| Unitedhealth Group Incorporated | 4.78% | 7.51% | 14.55% |
| Futu Holdings Ltd | 4.95% | 19.69% | 28.25% |
| Elevance Health Inc | 3.99% | 6.09% | 11.19% |
| Marsh and Mclennan Companies Inc | 6.90% | 11.32% | 26.71% |
| The Cigna Group | 4.46% | 6.88% | 16.50% |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Unum Group's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Unum Group | 21.39 | 1.09 |
| Unitedhealth Group Incorporated | 24.31 | 0.76 |
| Futu Holdings Ltd | 87.03 | 43.25 |
| Elevance Health Inc | 17.56 | 0.43 |
| Marsh and Mclennan Companies Inc | 20.71 | 2.91 |
| The Cigna Group | 11.27 | 0.25 |
| PEERS AVERAGE | 8.06 | 0.68 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.